دورية أكاديمية
Nebivolol therapy improves QTc and QTcd parameters in heart failure patients.
| العنوان: | Nebivolol therapy improves QTc and QTcd parameters in heart failure patients. |
|---|---|
| المؤلفون: | Aksoy SM; Department of Anesthesiology, Diskapi Yildirim Beyazit Education and Research Hospital, Ankara, Turkey., Cay S, Cagirci G, Sen N |
| المصدر: | Cardiovascular journal of Africa [Cardiovasc J Afr] 2012 May; Vol. 23 (4), pp. 191-3. |
| نوع المنشور: | Comparative Study; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Clinics Cardive Pub Country of Publication: South Africa NLM ID: 101313864 Publication Model: Print Cited Medium: Internet ISSN: 1680-0745 (Electronic) Linking ISSN: 10159657 NLM ISO Abbreviation: Cardiovasc J Afr Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Durbanville : Clinics Cardive Pub. |
| مواضيع طبية MeSH: | Benzopyrans/*therapeutic use , Electrocardiography/*drug effects , Ethanolamines/*therapeutic use , Heart Conduction System/*physiopathology , Heart Failure/*drug therapy , Ventricular Function, Left/*drug effects, Adrenergic beta-Antagonists/therapeutic use ; Aged ; Female ; Follow-Up Studies ; Heart Conduction System/drug effects ; Heart Failure/physiopathology ; Humans ; Male ; Nebivolol ; Platelet Aggregation Inhibitors ; Treatment Outcome |
| مستخلص: | Aim: It has previously been shown that β-blocker therapy reduces QT dynamics in heart failure patients. The aim of this study was to demonstrate this improvement with the third-generation β-blocker, nebivolol. Methods: A total of 72 heart failure patients with systolic dysfunction were included in the study. Corrected QT (QTc) and QT dispersion (QTcd) were measured manually by two independent observers at baseline and after nebivolol use (5 mg/day) in the first and third months of follow up. Results: Both QTc and QTcd were found to be significantly reduced in the first (455.3 ± 26.7 vs 441.2 ± 25.7 ms, p < 0.001 for QTc, and 65.6 ± 5.3 vs 58.2 ± 5.6 ms, p = 0.001 for QTcd) and third months (455.3 ± 26.7 vs 436.0 ± 28.7 ms, p < 0.001 for QTc, and 65.6 ± 5.3 vs 56.0 ± 6.2 ms, p < 0.001 for QTcd) compared with baseline values. Conclusion: Nebivolol was associated with improved QT dynamics in heart failure patients with systolic dysfunction. |
| References: | Lancet. 1994 Feb 5;343(8893):327-9. (PMID: 7905146) Am J Cardiol. 1998 Apr 1;81(7):924-6. (PMID: 9555785) Eur Heart J. 2005 Feb;26(3):215-25. (PMID: 15642700) Heart. 1997 Jun;77(6):539-42. (PMID: 9227298) J Cardiovasc Pharmacol Ther. 2001 Apr;6(2):107-10. (PMID: 11509916) Cardiovasc Drug Rev. 2004 Fall;22(3):155-68. (PMID: 15492765) Eur Heart J. 1996 Jul;17(7):1035-9. (PMID: 8809521) J Am Coll Cardiol. 2004 Oct 6;44(7):1481-7. (PMID: 15464332) Lancet. 1999 Jun 12;353(9169):2001-7. (PMID: 10376614) Lancet. 1999 Jan 2;353(9146):9-13. (PMID: 10023943) Blood Press Suppl. 2004 Oct;1:17-32. (PMID: 15587108) Circulation. 2003 Apr 8;107(13):1764-9. (PMID: 12665499) Int J Cardiol. 2010 Apr 15;140(2):255-7. (PMID: 19042044) N Engl J Med. 2001 May 31;344(22):1651-8. (PMID: 11386263) Heart. 1999 Mar;81(3):297-302. (PMID: 10026356) Am J Cardiol. 1997 Feb 1;79(3):328-33. (PMID: 9036753) Eur Heart J. 1991 Mar;12(3):423-7. (PMID: 2040324) Biomed Pharmacother. 2005 Jan-Feb;59(1-2):15-9. (PMID: 15740930) |
| المشرفين على المادة: | 0 (Adrenergic beta-Antagonists) 0 (Benzopyrans) 0 (Ethanolamines) 0 (Platelet Aggregation Inhibitors) 030Y90569U (Nebivolol) |
| تواريخ الأحداث: | Date Created: 20120523 Date Completed: 20130206 Latest Revision: 20211021 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC3721958 |
| DOI: | 10.5830/CVJA-2011-046 |
| PMID: | 22614660 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1680-0745 |
|---|---|
| DOI: | 10.5830/CVJA-2011-046 |